XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2018 |  | 2017
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® |  | $ | 1,242 |  |  | $ | 50 |  |  | $ | 1,292 |  |  | $ | 1,309 |  |  | $ | 54 |  |  | $ | 1,363 |
Neulasta® |  | 897 |  |  | 154 |  |  | 1,051 |  |  | 977 |  |  | 146 |  |  | 1,123 |
Prolia® |  | 354 |  |  | 178 |  |  | 532 |  |  | 298 |  |  | 166 |  |  | 464 |
Aranesp® |  | 248 |  |  | 229 |  |  | 477 |  |  | 285 |  |  | 231 |  |  | 516 |
XGEVA® |  | 323 |  |  | 110 |  |  | 433 |  |  | 282 |  |  | 105 |  |  | 387 |
Sensipar® / Mimpara® |  | 330 |  |  | 79 |  |  | 409 |  |  | 373 |  |  | 84 |  |  | 457 |
EPOGEN® |  | 252 |  |  | — |  |  | 252 |  |  | 264 |  |  | — |  |  | 264 |
Other products |  | 614 |  |  | 450 |  |  | 1,064 |  |  | 509 |  |  | 370 |  |  | 879 |
Total product sales(1) |  | $ | 4,260 |  |  | $ | 1,250 |  |  | $ | 5,510 |  |  | $ | 4,297 |  |  | $ | 1,156 |  |  | $ | 5,453 |
Other revenues |  |  |  |  |  | 394 |  |  |  |  |  |  | 320 |
Total revenues(2) |  |  |  |  |  | $ | 5,904 |  |  |  |  |  |  | $ | 5,773 |
|  | Nine months ended September 30,
|  | 2018 |  | 2017
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® |  | $ | 3,544 |  |  | $ | 155 |  |  | $ | 3,699 |  |  | $ | 3,838 |  |  | $ | 172 |  |  | $ | 4,010 |
Neulasta® |  | 2,854 |  |  | 452 |  |  | 3,306 |  |  | 2,962 |  |  | 458 |  |  | 3,420 |
Prolia® |  | 1,070 |  |  | 566 |  |  | 1,636 |  |  | 903 |  |  | 491 |  |  | 1,394 |
Aranesp® |  | 714 |  |  | 689 |  |  | 1,403 |  |  | 851 |  |  | 711 |  |  | 1,562 |
XGEVA® |  | 994 |  |  | 336 |  |  | 1,330 |  |  | 872 |  |  | 312 |  |  | 1,184 |
Sensipar® / Mimpara® |  | 1,069 |  |  | 257 |  |  | 1,326 |  |  | 1,052 |  |  | 253 |  |  | 1,305 |
EPOGEN® |  | 746 |  |  | — |  |  | 746 |  |  | 826 |  |  | — |  |  | 826 |
Other products |  | 1,783 |  |  | 1,303 |  |  | 3,086 |  |  | 1,474 |  |  | 1,051 |  |  | 2,525 |
Total product sales(1) |  | $ | 12,774 |  |  | $ | 3,758 |  |  | $ | 16,532 |  |  | $ | 12,778 |  |  | $ | 3,448 |  |  | $ | 16,226 |
Other revenues |  |  |  |  |  | 985 |  |  |  |  |  |  | 821 |
Total revenues(2) |  |  |  |  |  | $ | 17,517 |  |  |  |  |  |  | $ | 17,047 |
____________
(1) | Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.
(2) | Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration